The DOI matches its Crossref record; 335 of the 335 references it cites were found in a registry or an index.
AAV vectors: The Rubik’s cube of human gene therapy
Open accessAbstract
Defective genes account for ∼80% of the total of more than 7,000 diseases known to date. Gene therapy brings the promise of a one-time treatment option that will fix the errors in patient genetic coding. Recombinant viruses are highly efficient vehicles for in vivo gene delivery. Adeno-associated virus (AAV) vectors offer unique advantages, such as tissue tropism, specificity in transduction, eliciting of a relatively low immune responses, no incorporation into the host chromosome, and long-lasting delivered gene expression, making them the most popular viral gene delivery system in clinical trials, with three AAV-based gene therapy drugs already approved by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA). Despite the success of AAV vectors, their usage in particular scenarios is still limited due to remaining challenges, such as poor transduction efficiency in certain tissues, low organ specificity, pre-existing humoral immunity to AAV capsids, and vector dose-dependent toxicity in patients. In the present review, we address the different approaches to improve AAV vectors for gene therapy with a focus on AAV capsid selection and engineering, strategies to overcome anti-AAV immune response, and vector genome design, ending with a glimpse at vector production methods and the current state of recombinant AAV (rAAV) at the clinical level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–335 of 335
Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort
Perocheau, D. P., Cunningham, S. C., Lee, J., Antinao Diaz, J., Waddington, S. N., Gilmour, K., Eaglestone, S., Lisowski, L., Thrasher, A. J., Alexander, I. E., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.098 · Cited by 81
Waldman, Y. Y., Tuller, T., Shlomi, T., Sharan, R., & Ruppin, E. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq009 · Cited by 81
Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.026 · Cited by 80 · cited 1×
“…between CpG content, immune system activation, and transgene elimination was corroborated in other gene therapy clinical trials for hemophilia B. 209 Therefore, fi nding the right balance between the potential increase of transgene expression and the number of immunostimulatory CpG motifs can be…”
BackgroundManufacturing Recombinant Adeno-Associated Viral Vectors from Producer Cell Clones
Thorne, B. A., Takeya, R. K., & PELUSO, R. W. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.070 · Cited by 80
Shirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
Majowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J. H., Konstantinova, P. S., & Ferreira, V. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2712 · Cited by 78
Isolation of targeted AAV2 vectors from novel virus display libraries
Waterkamp, D. A., Müller, O. J., Ying, Y., Trepel, M., & Kleinschmidt, J. A. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.967 · Cited by 78
Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
Grose, W. E., Clark, K. R., Griffin, D., Malik, V., Shontz, K. M., Montgomery, C. L., Lewis, S., Brown, R. H., Janssen, P. M. L., Mendell, J. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039233 · Cited by 76
Thwaite, R., Pagès, G., Chillón, M., & Bosch, A. (2015) · Gene Therapy · doi:10.1038/gt.2014.103 · Cited by 76 · cited 1×
“189 Due to this complex scenario, an important effort is being made in the design of novel AAV capsids or capsid modi fi cation strategies directed to avoid Nabs, as discussed elsewhere in this review.”
BackgroundCNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector
Murlidharan, G., Sakamoto, K., Rao, L., Corriher, T., Wang, D., Gao, G., Sullivan, P. M., & Asokan, A. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.49 · Cited by 76
Michelfelder, S., Kohlschütter, J., Skorupa, A., Pfennings, S., Müller, O. J., Kleinschmidt, J. A., & Trepel, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005122 · Cited by 75
AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials
Hardcastle, N., Boulis, N. M., & Federici, T. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1416089 · Cited by 75
Virág, T., Cecchini, S., & Kotin, R. M. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.092 · Cited by 73
Ronzitti, G., Bortolussi, G., van Dijk, R., Collaud, F., Charles, S., Leborgne, C., Vidal, P., Martin, S., Gjata, B., Sola, M. S., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.49 · Cited by 72
Pre-arrayed Pan-AAV Peptide Display Libraries for Rapid Single-Round Screening
Börner, K., Kienle, E., Huang, L., Weinmann, J., Sacher, A., Bayer, P., Stüllein, C., Fakhiri, J., Zimmermann, L., Westhaus, A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.02.009 · Cited by 72
Structure–function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6)
Xie, Q., Lerch, T. F., Meyer, N., & Chapman, M. S. (2011) · Virology · doi:10.1016/j.virol.2011.08.011 · Cited by 71
Critical assessment of current adeno-associated viral vector production and quantification methods
Aucoin, M. G., Perrier, M., & Kamen, A. (2007) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.09.001 · Cited by 71
Li, M., Jayandharan, G. R., Li, B., Ling, C., Ma, W., Srivastava, A., & Li, Z. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.005 · Cited by 71
Yao, T., Zhou, X., Zhang, C., Yu, X., Tian, Z., Zhang, L., & Zhou, D. (2017) · Molecules · doi:10.3390/molecules22071155 · Cited by 68
AAV-S: A versatile capsid variant for transduction of mouse and primate inner ear
Ivanchenko, M. V., Hanlon, K. S., Hathaway, D. M., Klein, A. J., Peters, C. W., Li, Y., Tamvakologos, P. I., Nammour, J., Maguire, C. A., & Corey, D. P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.019 · Cited by 68
The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
Jin, C., Fotaki, G., Ramachandran, M., Nilsson, B., Essand, M., & Yu, D. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505869 · Cited by 66
Zhang, X., He, T., Chai, Z., Samulski, R. J., & Li, C. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.041 · Cited by 65
Self-citationZhang, A.-H., Rossi, R. J., Yoon, J., Wang, H., & Scott, D. W. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.004 · Cited by 65
Jin, X., Liu, L., Nass, S., O’Riordan, C. R., Pastor, E., & Zhang, X. K. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.178 · Cited by 65
Roudaut, C., Roy, F. L., Suel, L., Poupiot, J., Charton, K., Bartoli, M., & Richard, I. (2013) · Circulation · doi:10.1161/circulationaha.113.001340 · Cited by 63
Oversized AAV Transductifon Is Mediated via a DNA-PKcs-independent, Rad51C-dependent Repair Pathway
Hirsch, M. L., Li, C., Bellon, I., Yin, C., Chavala, S., Pryadkina, M., Richard, I., & Samulski, R. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.184 · Cited by 62
Self-citationStachler, M. D., Chen, I., Ting, A. Y., & Bartlett, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.129 · Cited by 61
Site‐Specific Modification of Adeno‐Associated Viruses via a Genetically Engineered Aldehyde Tag
Liu, Y., Fang, Y. H., Zhou, Y., Zandi, E., Lee, C.-L., Joo, K., & Wang, P. (2012) · Small · doi:10.1002/smll.201201661 · Cited by 61
Patrício, M. I., Barnard, A. R., Orlans, H. O., McClements, M. E., & MacLaren, R. E. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.006 · Cited by 61
Next-generation muscle-directed gene therapy by in silico vector design
Sarcar, S., Tulalamba, W., Rincón, M. Y., Tipanee, J., Pham, H. Q., Evens, H., Boon, D., Samara-Kuko, E., Keyaerts, M., Loperfido, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08283-7 · Cited by 61
Pooled Screens Identify GPR108 and TM9SF2 as Host Cell Factors Critical for AAV Transduction
Meisen, W. H., Bahrami-Nejad, Z., Hardy, M., Zhao, H., Oliverio, O., Wang, S., Hale, C. M., Ollmann, M. M., & Collins, P. J. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.012 · Cited by 61
Han, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60
MicroRNA-Restricted Transgene Expression in the Retina
Karali, M., Manfredi, A., Puppo, A., Marrocco, E., Gargiulo, A., Allocca, M., Corte, M. D., Rossi, S., Giunti, M., Bacci, M. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022166 · Cited by 60
Watanabe, S., Sanuki, R., Ueno, S., Koyasu, T., Hasegawa, T., & Furukawa, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054146 · Cited by 59
Woodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59
Self-citationManufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines
Kotin, R. M., & Snyder, R. O. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.042 · Cited by 59
Rosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58
Bouças, J., Lux, K., Huber, A., Schievenbusch, S., von Freyend, M. J., Perabò, L., Quadt‐Humme, S., Odenthal, M., Hallek, M. J., & Büning, H. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1392 · Cited by 58
Dayton, R. D., Grames, M. S., & Klein, R. L. (2018) · Gene Therapy · doi:10.1038/s41434-018-0028-5 · Cited by 58
Wang, D., Zhong, L., Li, M., Li, J., Tran, K., Ren, L., He, R., Xie, J., Moser, R. P., Fraser, C. K., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.09.003 · Cited by 58
Oligonucleotide conjugated multi-functional adeno-associated viruses
Katrekar, D., Moreno, A. M., Chen, G., Worlikar, A., & Mali, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-21742-x · Cited by 57
Havlik, L. P., Simon, K. E., Smith, J. K., Klinc, K. A., Tse, L. V., Oh, D. K., Fanous, M. M., Meganck, R. M., Mietzsch, M., Kleinschmidt, J. A., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00976-20 · Cited by 57
Liu, A. P., Patel, S. K., Xing, T., Yan, Y., Wang, S., & Li, N. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113481 · Cited by 57
Ilyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy
Yang, Y.-S., Xie, J., Chaugule, S. R., Wang, D., Kim, J., Kim, J., Tai, P. W. L., Seo, S. K., Gravallese, E. M., Gao, G., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.010 · Cited by 55
Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy
Sallach, J., Pasquale, G. D., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S. A., Ulus, H., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.14 · Cited by 54
Leborgne, C., Latournerie, V., Boutin, S., Desgue, D., Quéré, A., Pignot, E., Collaud, F., Charles, S., Sola, M. S., Masat, E., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.004 · Cited by 54
Adipose Tissue: An Emerging Target for Adeno-associated Viral Vectors
Bates, R., Huang, W., & Cao, L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.009 · Cited by 54
Charbel Issa, P., De Silva, S. R., Lipinski, D. M., Singh, M. S., Mouravlev, A., You, Q., Barnard, A. R., Hankins, M. W., During, M. J., & MacLaren, R. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060361 · Cited by 53 · cited 2×
“113 These vectors were originally selected for retinal tissue transduction, where they are ef fi cient, but no more so than AAV2 and AAV5.”
BackgroundPryadkina, M., Lostal, W., Bourg, N., Charton, K., Roudaut, C., Hirsch, M. L., & Richard, I. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.9 · Cited by 53
Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O. J., Kleinschmidt, J. A., & Trepel, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023101 · Cited by 53
Early Insights from Commercialization of Gene Therapies in Europe
Touchot, N., & Flume, M. (2017) · Genes · doi:10.3390/genes8020078 · Cited by 53
Sen, D., Gadkari, R. A., Sudha, G., Gabriel, N., Kumar, Y. S., Selot, R., Samuel, R., Rajalingam, S., Ramya, V., Nair, S. C., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.195 · Cited by 51
Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype
Liu, X., Magee, D., Wang, C., McMurphy, T. B., Slater, A., During, M. J., & Cao, L. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.8 · Cited by 51
Site-Specific N-Glycosylation on the AAV8 Capsid Protein
Aloor, A., Zhang, J., Gashash, E. A., Parameswaran, A., Chrzanowski, M., Ma, C., Diao, Y., Wang, P. G., & Xiao, W. (2018) · Viruses · doi:10.3390/v10110644 · Cited by 51
Schiedner, G., Hertel, S., Bialek, C., Kewes, H., Waschütza, G., & Volpers, C. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-13 · Cited by 50
Neurotropic Properties of AAV-PHP.B Are Shared among Diverse Inbred Strains of Mice
Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., & Hirai, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.016 · Cited by 50
Penaud‐Budloo, M., Lecomte, É., Guy‐Duché, A., Saleün, S., Roulet, A., Lopez‐Roques, C., Tournaire, B., Cogné, B., Léger, A., Blouin, V., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.185 · Cited by 49
Mazor, R., King, E. M., Onda, M., Çuburu, N., Addissie, S., Crown, D., Liu, X., Kishimoto, T., & Pastan, I. H. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717063115 · Cited by 49
Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy
Sen, D., Balakrishnan, B., Gabriel, N., Agrawal, P. P., Roshini, V., Samuel, R., Srivastava, A., & Jayandharan, G. R. (2013) · Scientific Reports · doi:10.1038/srep01832 · Cited by 48
Recombinant Viral Vectors as Neuroscience Tools
Chen, S., Haam, J., Walker, M., Scappini, E., Naughton, J., & Martin, N. P. (2019) · Current Protocols in Neuroscience · doi:10.1002/cpns.67 · Cited by 48
Ling, C., Wang, Y., Lu, Y., Wang, L., Jayandharan, G. R., Aslanidi, G. V., Li, B., Cheng, B., Ma, W., Lentz, T., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02581-14 · Cited by 47
Self-citationChen, L., Zhu, F., Li, J., Lu, H., Jiang, H., Sarkar, R., Arruda, V. R., Wang, J., Zhao, J., Pierce, G. F., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300268 · Cited by 46
Evaluation of AAV-DJ vector for retinal gene therapy
Katada, Y., Kobayashi, K., Tsubota, K., & Kurihara, T. (2019) · PeerJ · doi:10.7717/peerj.6317 · Cited by 46
Zhu, J., Pan, T., Mahalingam, M., Sha, J., Kilgore, P. B., Chopra, A. K., & Rao, V. B. (2019) · Science Advances · doi:10.1126/sciadv.aax0064 · Cited by 46
Lin, K., Zhong, X., Li, L., Ying, M., Yang, T., Zhang, Z., He, X., & Xu, F. (2020) · Molecular Brain · doi:10.1186/s13041-020-00679-1 · Cited by 45
Murray, S., Nilsson, C. L., Hare, J. T., Emmett, M. R., Korostelev, A. A., Ongley, H. M., Marshall, A. G., & Chapman, M. S. (2006) · Journal of Virology · doi:10.1128/jvi.02417-05 · Cited by 43
Greig, J. A., Wang, Q., Reicherter, A. L., Chen, S., Hanlon, A. L., Tipper, C. H., Clark, K. R., Wadsworth, S. C., Wang, L., & Wilson, J. M. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.128 · Cited by 43
Adeno-Associated Virus Vectors and Stem Cells: Friends or Foes?
Brown, N. J., Song, L., Rao, K. N., & Hirsch, M. L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.038 · Cited by 43
Hagedorn, C., Schnoedt, M., Boehme, P., Abdelrazik, H., Lipps, H. J., & Büning, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.025 · Cited by 41
Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery
Pietersz, K. L., Martier, R., Baatje, M. S., Liefhebber, J. M. P., Brouwers, C. C., Pouw, S. M., Fokkert, L., Lubelski, J., Petry, H., Martens, G. J. M., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-0178-0 · Cited by 41
Glycated AAV vectors: chemical redirection of viral tissue tropism
Horowitz, E. D., Weinberg, M. S., & Asokan, A. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100477g · Cited by 40 · cited 3×
“150 This reaction disrupted the cluster of basic amino acid residues implicated in heparan sulfate binding in AAV2.”
BackgroundInfluentialDevelopment of novel AAV serotype 6 based vectors with selective tropism for human cancer cells
Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., & Aslanidi, G. (2015) · Gene Therapy · doi:10.1038/gt.2015.89 · Cited by 40
A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors
Qizhao, W., Wu, Z., Zhang, J., Firrman, J., Wei, H., Zhuang, Z., Liu, L., Miao, L., Hu, Y., Li, D., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.002 · Cited by 40
DNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations
Schnödt, M., Schmeer, M., Kracher, B., Krüsemann, C., Espinosa, L. E., Grünert, A., Fuchsluger, T., Rischmüller, A., Schleef, M., & Büning, H. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.60 · Cited by 39
Verghese, S. C., Goloviznina, N. A., Skinner, A. M., Lipps, H. J., & Kurre, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku082 · Cited by 38
Ho, M. L., Adler, B. A., Torre, M. L., Silberg, J. J., & Suh, J. (2013) · ACS Synthetic Biology · doi:10.1021/sb400076r · Cited by 37
Luteijn, R. D., van Diemen, F. R., Blomen, V. A., Boer, I. G. J., Sadasivam, S. M., Kuppevelt, T. H. V., Drexler, I., Brummelkamp, T. R., Lebbink, R. J., & Wiertz, E. J. H. J. (2019) · Journal of Virology · doi:10.1128/jvi.02160-18 · Cited by 37
Qian, R., Xiao, B., Li, J., & Xiao, X. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.010 · Cited by 37
Trepel, M., Körbelin, J., Spies, E., Heckmann, M. B., Hunger, A., Fehse, B., Katus, H. A., Kleinschmidt, J. A., Müller, O. J., & Michelfelder, S. (2015) · Gene Therapy · doi:10.1038/gt.2015.52 · Cited by 36
Cross-Packaging and Capsid Mosaic Formation in Multiplexed AAV Libraries
Schmit, P. F., Pacouret, S., Zinn, E. M., Telford, E., Nicolaou, F., Broucque, F., Andrés‐Mateos, E., Xiao, R., Penaud‐Budloo, M., Bouzelha, M., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.014 · Cited by 36
Kurasawa, J. H., PARK, A. W., Sowers, C. R., Halpin, R., Tovchigrechko, A., Dobson, C., Schmelzer, A. E., Gao, C., Wilson, S. D., & Ikeda, Y. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.018 · Cited by 36
Adamson-Small, L. A., Potter, M., Byrne, B. J., & Clément, N. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.151 · Cited by 35
Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity
Pei, X., Shao, W., Xing, A., Askew, C., Chen, X., Cui, C., Abajas, Y. L., Gerber, D. A., Merricks, E. P., Nichols, T. C., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.003 · Cited by 35
Self-citationDevelopment of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B
Brown, H. C., Doering, C. B., Herzog, R. W., Ling, C., Markusic, D. M., Spencer, H. T., Srivastava, A., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.099 · Cited by 34
Reducing the Risk of Adeno-Associated Virus (AAV) Vector Mobilization with AAV Type 5 Vectors
Hewitt, F. C., Li, C., Gray, S. J., Cockrell, S. K., Washburn, M. L., & Samulski, R. J. (2009) · Journal of Virology · doi:10.1128/jvi.02466-08 · Cited by 33
Self-citationAAV6 Vexosomes Mediate Robust Suicide Gene Delivery in a Murine Model of Hepatocellular Carcinoma
Khan, N., Maurya, S., Bammidi, S., & Jayandharan, G. R. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.006 · Cited by 33
Two-Plasmid Packaging System for Recombinant Adeno-Associated Virus
Tang, Q., Keeler, A. M., Zhang, S., Su, Q., Lyu, Z., Cheng, Y., Gao, G., & Flotte, T. R. (2020) · BioResearch open access · doi:10.1089/biores.2020.0031 · Cited by 33
Meng, Y., Sun, D., Qin, Y., Dong, X., Luo, G., & Liu, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.019 · Cited by 33
Optimization of Adeno-Associated Viral Vector-Mediated Gene Delivery to the Hypothalamus
de Backer, M. W. A., Brans, M. A. D., Luijendijk, M. C. M., Garner, K. M., & Adan, R. A. H. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.169 · Cited by 32
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Self-citationBackovic, A., Cervelli, T., Salvetti, A., Zentilin, L., Giacca, M., & Galli, A. (2012) · Microbial Cell Factories · doi:10.1186/1475-2859-11-124 · Cited by 30
Gene Therapy - Principles and Challenges
Hashad, D. I. (2015) · InTech eBooks · doi:10.5772/59824 · Cited by 30
Silveria, M., Large, E. E., Zane, G. M., White, T., & Chapman, M. S. (2020) · Viruses · doi:10.3390/v12111326 · Cited by 30
Liu, Z., Klose, K., Neuber, S., Jiang, M., Gossen, M., & Stamm, C. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02605-4 · Cited by 30
Efficient AAV1–AAV2 Hybrid Vector for Gene Therapy of Hemophilia
Hauck, B., Xu, R. R., Xie, J., Wu, W., Ding, Q., Sipler, M., Wang, H., Chen, L., Wright, J. F., & Xiao, W. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.46 · Cited by 29
Mays, L. E., Wang, L., Tenney, R. M., Bell, P. L., Nam, H.-J., Lin, J., Gurda, B. L., Vliet, K. V., Mikals, K., Agbandje‐McKenna, M., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00596-13 · Cited by 29
Chinn, L. W., Tang, M., Kessing, B. D., Lautenberger, J. A., Troyer, J. L., Malasky, M., MCINTOSH, C. E., Kirk, G. D., Wolinsky, S. M., Buchbinder, S., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/657322 · Cited by 29
Chai, Z., Sun, J., Rigsbee, K. M., Wang, M., Samulski, R. J., & Li, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.005 · Cited by 29
Self-citationPipe, S. W., Stine, K. C., Rajasekhar, A., Everington, T., Poma, A., Crombez, E. A., & Hay, C. R. M. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.3331.3331 · Cited by 29
Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors
Ling, C., Yin, Z., Li, J., Zhang, D., Aslanidi, G., & Srivastava, A. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.29 · Cited by 28
Generation of infectious recombinant Adeno-associated virus in Saccharomyces cerevisiae
Barajas, D., Aponte, J. J., Akeefe, H., Cinek, T., Peltier, J., & Gold, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173010 · Cited by 28
Doggybone™ DNA: an advanced platform for AAV production
Karbowniczek, K., Rothwell, P. J., Extance, J., Milsom, S., Lukashchuk, V., Bowes, K., Smith, D. P., & Caproni, L. J. (2017) · Cell and Gene Therapy Insights · doi:10.18609/cgti.2017.074 · Cited by 28
Viney, L., Bürckstümmer, T., Eddington, C., Mietzsch, M., Choudhry, M. S., Henley, T., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.02023-20 · Cited by 27
Bell, P., Wang, L., Chen, S.-J., Yu, H., Zhu, Y., Nayal, M., He, Z., White, J., Lebel-Hagan, D., & Wilson, J. M. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.039 · Cited by 26
Lu, J., Williams, J. A., Luke, J., Zhang, F., Chu, K., & Kay, M. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.140 · Cited by 26
Sellner, L., Stiefelhagen, M., Kleinschmidt, J. A., Laufs, S., Wenz, F. K., Früehauf, S., Zeller, W. J., & Veldwijk, M. R. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.03.007 · Cited by 25
Optimizing delivery for efficient cardiac reprogramming
Kang, M. H., Hu, J., Pratt, R. E., Hodgkinson, C. P., Asokan, A., & Dzau, V. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.104 · Cited by 22
Unique Glycan Signatures Regulate Adeno-Associated Virus Tropism in the Developing Brain
Murlidharan, G., Corriher, T., Ghashghaei, H. T., & Asokan, A. (2015) · Journal of Virology · doi:10.1128/jvi.02951-14 · Cited by 21
Tang, Y., Yan, Z., Lin, S., Huntemann, E. D., Feng, Z., Park, S.-Y., Sun, X., Yuen, E., & Engelhardt, J. F. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.008 · Cited by 21
Chen, Q., Luo, H., Zhou, C., Yu, H., Yao, S., Fu, F., Seeley, R. A., Ji, X., Yang, Y., Chen, P., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243359 · Cited by 21
Körbelin, J., Hunger, A., Alawi, M., Sieber, T., Binder, M., & Trepel, M. (2017) · Gene Therapy · doi:10.1038/gt.2017.51 · Cited by 20
Palaschak, B., Marsic, D., Herzog, R. W., Zolotukhin, S., & Markusic, D. M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.004 · Cited by 19
AAV vectors engineered to target insulin receptor greatly enhance intramuscular gene delivery
Jackson, C. B., Richard, A. S., Ojha, A., Conkright, K. A., Trimarchi, J. M., Bailey, C. C., Alpert, M. D., Kay, M. A., Farzan, M., & Choe, H. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.004 · Cited by 19
Rumachik, N. G., Malaker, S. A., & Paulk, N. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657795 · Cited by 19
Kyostio-Moore, S., Berthelette, P., Piraino, S., Sookdeo, C., Nambiar, B., Jackson, R., Burnham, B. L., O’Riordan, C. R., Cheng, S. H., & Armentano, D. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.6 · Cited by 18
Siu, J. J., Queen, N. J., Huang, W., Yin, F., Liu, X., Wang, C., McTigue, D. M., & Cao, L. (2017) · Gene Therapy · doi:10.1038/gt.2017.27 · Cited by 18
Robinson, T. M., Ho, M. L., Wahlig, B. D., Gough, V., Banta, A. R., Gamas, K. R., Kang, B., Lee, E., Chen, W., & Suh, J. (2020) · Virology · doi:10.1016/j.virol.2020.04.008 · Cited by 18
Colon-Cortes, Y., Hasan, M. A., & Aslanidi, G. (2020) · Gene · doi:10.1016/j.gene.2020.100037 · Cited by 17
Gene therapies advance towards finish line
Mullard, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3572 · Cited by 16
Sites in the AAV5 capsid tolerant to deletions and tandem duplications
Hida, K., Won, S. Y., Pasquale, G. D., Hanes, J. S., Chiorini, J. A., & Ostermeier, M. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.01.009 · Cited by 16
Reid, C. A., Boye, S. L., Hauswirth, W. W., & Lipinski, D. M. (2017) · Gene Therapy · doi:10.1038/gt.2017.50 · Cited by 16
Peptide affinity reagents for AAV capsid recognition and purification
Pulicherla, N., & Asokan, A. (2011) · Gene Therapy · doi:10.1038/gt.2011.46 · Cited by 15
Advances and challenges in developing a therapy for spinal muscular atrophy
Anderton, R. S., & Mastaglia, F. L. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1059757 · Cited by 13
How to Successfully Screen Random Adeno-Associated Virus Display Peptide Libraries In Vivo
Körbelin, J., & Trepel, M. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.177 · Cited by 13
Thadani, N. N., Yang, J., Moyo, B., Lee, C. M., Chen, M. Y., Bao, G., & Suh, J. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00341 · Cited by 13
Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors
Chai, Z., Zhang, X., Dobbins, A. L., Frost, E. A., Samulski, R. J., & Li, C. (2019) · Viruses · doi:10.3390/v11121138 · Cited by 11
Self-citationGalli, A., Latta, V. D., Bologna, C., Pucciarelli, D., Cipriani, F., Backovic, A., & Cervelli, T. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13511 · Cited by 10
The Use of Functional Genomics in Synthetic Promoter Design
Michael, L. (2011) · InTech eBooks · doi:10.5772/20653 · Cited by 8
Tabata, K., Sugano, E., Murakami, F., Yamashita, T., Ozaki, T., & Tomita, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.014 · Cited by 7
Emmerling, V. V., Holzmann, K., Lanz, K., Kochanek, S., & Hörer, M. (2013) · BMC Proceedings · doi:10.1186/1753-6561-7-s6-p12 · Cited by 5
Fusion of Anthopleurin-B to AAV2 increases specificity of cardiac gene transfer
Finet, J. E., Wan, X., & Donahue, J. K. (2017) · Virology · doi:10.1016/j.virol.2017.10.006 · Cited by 4
Recent advances in non-viral vectors for gene therapy & vaccination
Hodgson, C. P., Carnes, A. E., & Williams, J. A. (2017) · Cell and Gene Therapy Insights · doi:10.18609/cgti.2017.012 · Cited by 1
Cited by
Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches
Leal, A., Herreno-Pachón, A., Benincore-Flórez, E., Karunathilaka, A., & Tomatsu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052456 · Cited by 58
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
Eukaryotic-driven directed evolution of Cas9 nucleases
(2024) · doi:10.1186/s13059-024-03215-9 · Cited by 15
Metadata
- Authors
- Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 30
- Issue
- 12
- Pages
- 3515-3541
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W4302028035
- Cited by
- 360
- References
- 335
- FWCI
- 38.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.